证券日报网讯12月16日，正海生物（300653）在互动平台回答投资者提问时表示，公司与江苏集萃研究 所合作开展的"重组生物活性蛋白产品的研究开发"项目正稳步推进中，不存在终止合作的情形。两项合 作开发项目具有不同的研发方向及技术路径，都是公司为丰富产品矩阵、提升长期竞争力的战略举措。 ...

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问公司先前与江苏集萃签署过关于重组蛋白的委托 开发合同进展如何？现在又与农科院签署委托开发合同是代表与之前的合作方终止合作么？还是双方同 时合作，分别承担不同的研发部分？ 正海生物（300653.SZ）12月16日在投资者互动平台表示，您好！公司与江苏集萃研究所合作开展的"重 组生物活性蛋白产品的研究开发"项目正稳步推进中，不存在终止合作的情形。两项合作开发项目具有 不同的研发方向及技术路径，都是公司为丰富产品矩阵、提升长期竞争力的战略举措。 ...

Core Viewpoint - The company is making steady progress on its research and development project for recombinant bioactive protein products in collaboration with Jiangsu Jicui Research Institute, aiming to establish a recombinant protein technology platform and expand its product pipeline [1] Group 1 - The project focuses on the development of recombinant protein-related technology [1] - The goal is to broaden the research and development pipeline to support the creation of more valuable product matrices [1]

Core Viewpoint - The company, Zhenghai Biological, announced on October 27 that it is steadily advancing its research and development project on "recombinant bioactive protein products" in collaboration with Jiangsu Jicui Research Institute, and will fulfill its information disclosure obligations upon any relevant progress [1] Group 1 - The collaboration with Jiangsu Jicui Research Institute focuses on the development of recombinant bioactive protein products [1] - The project is reported to be progressing steadily [1] - The company commits to timely information disclosure regarding any future developments related to the project [1]